KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Resmed (RMD) Accumulated Depreciation & Amortization (2016 - 2025)

Resmed (RMD) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $97.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 110.13% year-over-year to $97.6 million, compared with a TTM value of $97.6 million through Dec 2025, up 110.13%, and an annual FY2025 reading of $198.5 million, up 12.21% over the prior year.
  • Accumulated Depreciation & Amortization was $97.6 million for Q4 2025 at Resmed, up from $47.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $198.5 million in Q2 2025 and bottomed at $36.3 million in Q3 2022.
  • Average Accumulated Depreciation & Amortization over 5 years is $95.7 million, with a median of $88.7 million recorded in 2021.
  • Peak annual rise in Accumulated Depreciation & Amortization hit 110.13% in 2025, while the deepest fall reached 67.21% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $79.9 million in 2021, then tumbled by 52.73% to $37.8 million in 2022, then increased by 18.58% to $44.8 million in 2023, then rose by 3.7% to $46.4 million in 2024, then surged by 110.13% to $97.6 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for RMD at $97.6 million in Q4 2025, $47.7 million in Q3 2025, and $198.5 million in Q2 2025.